$PFE Recent Headlines Pfizer drops 2.5% to lead
Post# of 94265
Posted On: 04/07/2014 10:12:11 AM
$PFE Recent Headlines
Pfizer drops 2.5% to lead Dow decliners 36 min ago - William L. Watts
Questcor surges on buyout; MannKind sinks 8:28 a.m. Today - Ben Eisen
How sector stock funds can make your portfolio whole 7:01 a.m. Today - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch
Does Pfizer Belong in Your Portfolio? 8:34 a.m. Today - Wall St. Cheat Sheet
Pre-Market Laggard: Pfizer (PFE) 7:44 a.m. Today - TheStreet.com
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
MNKD Stock, Take Two: Volatility or Not, You Have to Like Afrezza 4:36 a.m. Today - InvestorPlace.com
Pfizer drug helps stop progression of breast cancer 3:56 a.m. Today - Seeking Alpha
Choose Your Route to Sector Investing 4:00 p.m. April 6, 2014 - The Wall Street Journal Interactive Edition
Pfizer, Lilly Drugs Show Promise in Slowing Breast Cancer 10:47 a.m. April 6, 2014 - The Wall Street Journal Interactive Edition
Coping With Wall Street's Fickle Nature,Yellow Flag for the IPO Hoopla: Jim Cramer's Best Blogs 1:10 p.m. April 5, 2014 - TheStreet.com
Supreme Court Studies Generic Drug Question: How Will Patients Fare? 6:19 p.m. April 4, 2014 - Wall St. Cheat Sheet
Merck KGaA and Auxogyn Collaborate - Analyst Blog 5:00 p.m. April 4, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, BMY, OXY 1:29 p.m. April 4, 2014 - TheStreet.com
Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs 8:31 a.m. April 4, 2014 - Seeking Alpha
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog 5:10 p.m. April 3, 2014 - Zacks.com
The Dow Earnings Season Mega-Chart 4:14 p.m. April 3, 2014 - TheStreet.com
PFE May 23rd Options Begin Trading 11:15 a.m. April 3, 2014 - TheStreet.com
Danger Zone: Value Investors 9:16 a.m. April 3, 2014 - Seeking Alpha
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. April 2, 2014 - TheStreet.com
China still bright for Big Pharma 11:30 a.m. April 2, 2014 - Seeking Alpha
Three Reasons to Be Cautious on Pfizer 10:02 a.m. April 2, 2014 - Barrons.com
Is It Too Early To Invest In Versartis? 9:08 a.m. April 2, 2014 - Seeking Alpha
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. Today - PR Newswire - PRF
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF
Pfizer drops 2.5% to lead Dow decliners 36 min ago - William L. Watts
Questcor surges on buyout; MannKind sinks 8:28 a.m. Today - Ben Eisen
How sector stock funds can make your portfolio whole 7:01 a.m. Today - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch
Does Pfizer Belong in Your Portfolio? 8:34 a.m. Today - Wall St. Cheat Sheet
Pre-Market Laggard: Pfizer (PFE) 7:44 a.m. Today - TheStreet.com
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
MNKD Stock, Take Two: Volatility or Not, You Have to Like Afrezza 4:36 a.m. Today - InvestorPlace.com
Pfizer drug helps stop progression of breast cancer 3:56 a.m. Today - Seeking Alpha
Choose Your Route to Sector Investing 4:00 p.m. April 6, 2014 - The Wall Street Journal Interactive Edition
Pfizer, Lilly Drugs Show Promise in Slowing Breast Cancer 10:47 a.m. April 6, 2014 - The Wall Street Journal Interactive Edition
Coping With Wall Street's Fickle Nature,Yellow Flag for the IPO Hoopla: Jim Cramer's Best Blogs 1:10 p.m. April 5, 2014 - TheStreet.com
Supreme Court Studies Generic Drug Question: How Will Patients Fare? 6:19 p.m. April 4, 2014 - Wall St. Cheat Sheet
Merck KGaA and Auxogyn Collaborate - Analyst Blog 5:00 p.m. April 4, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, BMY, OXY 1:29 p.m. April 4, 2014 - TheStreet.com
Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs 8:31 a.m. April 4, 2014 - Seeking Alpha
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog 5:10 p.m. April 3, 2014 - Zacks.com
The Dow Earnings Season Mega-Chart 4:14 p.m. April 3, 2014 - TheStreet.com
PFE May 23rd Options Begin Trading 11:15 a.m. April 3, 2014 - TheStreet.com
Danger Zone: Value Investors 9:16 a.m. April 3, 2014 - Seeking Alpha
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. April 2, 2014 - TheStreet.com
China still bright for Big Pharma 11:30 a.m. April 2, 2014 - Seeking Alpha
Three Reasons to Be Cautious on Pfizer 10:02 a.m. April 2, 2014 - Barrons.com
Is It Too Early To Invest In Versartis? 9:08 a.m. April 2, 2014 - Seeking Alpha
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. Today - PR Newswire - PRF
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF
(0)
(0)